Updates
Zydus receives final approval from USFDA05-06-2017
Cadila's US business hopes soar on Moraiya plant approval
The US market contributes around 40% to the company's revenues02-06-2017
Zydus Cadila gets USFDA nod for generic epilepsy drug
Zydus Cadila has received approval from US health regulator to market Felbamate tablets, used to treat seizures in people with epilepsy, in the American market. The company has received approval...31-05-2017
Fixes Book Closure for AGM
Cadila Healthcare Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 31, 2017 to August 11, 2017 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 11, 2017.30-05-2017
Cadila Healthcare posts Q4 net profit at Rs 385 crore
Consolidated total revenue of company stood at Rs 2,598 crore for quarter under consideration.27-05-2017
Outcome of Board Meeting
We are forwarding herewith a copy of the Press Release proposed to be published in the newspapers in the matter of audited financial results for the quarter / year ended on March 31, 2017.27-05-2017